Return to Home Incidence > Table > Interpret

Interpretation of Incidence Rates Data

Incidence Rate Report by State

Liver & Bile Duct (All Stages^), 2017-2021

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Name

Explanation of Column Headers

Objective - The objective of *** is from the Healthy People 2020 project done by the Centers for Disease Control and Prevention.

Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.

Recent Trends - This is an interpretation of the AAPC/APC:

AAPC/APC (95% Confidence Interval) - the change in rate over time


Other Notes


Line by Line Interpretation of the Report


US (SEER+NPCR)1


Wyoming6


Wisconsin6


West Virginia6


Washington5


Virginia6


Vermont6


Utah7


Texas7


Tennessee6


South Dakota6


South Carolina6


Rhode Island6


Puerto Rico6


Pennsylvania6


Oregon6


Oklahoma6


Ohio6


North Dakota6


North Carolina6


New York7


New Mexico7


New Jersey7


New Hampshire6


Nevada6


Nebraska6


Montana6


Missouri6


Mississippi6


Minnesota6


Michigan6


Massachusetts7


Maryland6


Maine6


Louisiana7


Kentucky7


Kansas6


Iowa7


Illinois7


Idaho7


Hawaii7


Georgia7


Florida6


District of Columbia6


Delaware6


Connecticut7


Colorado6


California7


Arkansas6


Arizona6


Alaska6


Alabama6


Indiana6

Notes:
Created by statecancerprofiles.cancer.gov on 12/02/2024 8:47 am.

State Cancer Registries may provide more current or more local data.

Data cannot be shown for the following areas. For more information on what areas are suppressed or not available, please refer to the table.
Indiana

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.
Rates and trends are computed using different standards for malignancy. For more information see malignant.html.

^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) Summary/Historic Combined Summary Stage (2004+).
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.
Source: SEER and NPCR data. For more specific information please see the table.

Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.